Medicalsystem Biotechnology Valuation
Is 300439 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300439 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300439 (CN¥9.7) is trading below our estimate of fair value (CN¥13.89)
Significantly Below Fair Value: 300439 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300439?
Other financial metrics that can be useful for relative valuation.
| What is 300439's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥3.72b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 7.6x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 300439's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 101.8x | ||
300653 Yantai Zhenghai Biotechnology | 22.5x | 17.6% | CN¥4.3b |
300238 Guanhao BiotechLtd | 108.4x | n/a | CN¥2.5b |
688293 Shanghai OPM Biosciences | 70.8x | 59.1% | CN¥3.8b |
688319 Chengdu Olymvax Biopharmaceuticals | 205.5x | 78.0% | CN¥3.6b |
300439 Medicalsystem Biotechnology | 14.1x | n/a | CN¥3.7b |
Price-To-Earnings vs Peers: 300439 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the peer average (101.8x).
Price to Earnings Ratio vs Industry
How does 300439's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Earnings vs Industry: 300439 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the CN Biotechs industry average (36x).
Price to Earnings Ratio vs Fair Ratio
What is 300439's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 300439's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.